tegideridine

Tegideridine (also known as SHR8554) is a novel, small-molecule G-protein biased μ-opioid receptor (MOR) agonist developed by Jiangsu Hengrui Pharmaceuticals. It is specifically designed for the management of moderate to severe acute postoperative pain. By selectively activating the G-protein signaling pathway while minimizing the recruitment of β-arrestin 2, tegideridine aims to provide potent analgesia with a significantly improved safety profile compared to traditional opioids like morphine. This biased signaling mechanism is intended to reduce the incidence of opioid-related adverse events, such as respiratory depression, nausea, vomiting, and gastrointestinal dysfunction (constipation). The drug received marketing approval from China's National Medical Products Administration (NMPA) in May 2023.

Brand names

Tajilidine

Other names

tegideridine fumaratefumarate tegideridine injectionTajiliding